【チューリッヒ】スイスの食品大手ネスレは26日、健康科学関連の子会社、ネスレ.ヘルス。サイエンスがうつ病治療に使われる医療食品を製造する米国のパムラボ(Pamlab、ルイジアナ州)を買収したと発表した。ネスレは脳やメタボ関連の医療食品事業を拡大する方針で、今回の買収もその一環だ。従業員は、300名、
パムラボは1957年の創業で、うつ病患者向けの一般的な医薬品と併用される混合ビタミン剤のメーカー。認知障害の患者向け食品の製造も行っている、
買収価格を明らかにしなかった。ネスレは高齢化社会に備えて急成長する栄養療法用食品市場での事業拡大を推進する、
Medical Foods – the emerging role of personalized medicine
Our products are unusual. In part because medical foods are a relatively new concept in the marketplace. Traditional medicine is approached as a "trial and error" method and is usually directed against the particular symptoms of the patient. Our approach is to look deeper into the underlying causes of their disease and/or medical condition. In so doing, we find that patients can often be grouped according to their genetic background. Such characteristics may reveal a predisposition to metabolic imbalances, enzyme deficiencies or various physiologic triggers that complicate their disease or condition. Pamlab believes that the future of pharmacology will become more personalized according to each patients genetic predisposition rather than a "one-size fits all" approach.
Key Disease States
Our research in medical foods has lead us to explore solutions for the distinct nutritional needs that some patients have in particular disease states. In most cases, the patient seeking treatment for his/her condition has a genetically-based inborn error of metabolism that has created a need for him/her to require certain nutrients to correct his/her metabolic imbalance.
Metanx is a medical food made by Pamlab that contains L-methylfolate (vitamin B9), methylcobalamin (vitamin B12) and pyridoxal 5'-phosphate (vitamin B6). It is a vitamin B supplement.
It is indicated for the treatment of endothelial dysfunction and hyperhomocysteinemia. In particular it has been shown to be an effective treatment for diabetic peripheral neuropathy[1][2] and lower extremity ulcerations such as diabetic foot ulcers.[3]
Metanx contains the following active ingredients (per tablet):
昨年、香港のハチソンワンポアの医薬品子会社と合弁
世界的に有名な食品グループNESTLEがLi Ka Shing(香港の億万長者)系の薬品会社Hutchison MediTechと共同で中国漢方の商品開発に取り組むそうです。
世界の漢方市場は約830億米ドル(約6兆8千億円)と言われております。その市場にリーチするためにHutchison MediTechが持つ5万種類以上の漢方薬エキスを活用し、今後の世界展開を予定しているわけです。
やはり中国人市場は今後購買層としては成長して行くと世界企業も読んでいるわけですね。漢方に限らず、中国人消費者向けの市場は魅力がまだまだありますよ!